Multicenter study of multi-parameter MRI and CT imaging combined with VI-RADS and artificial intelligence in diagnosis and efficacy evaluation of bladder cancer

Multicenter study of multi-parameter MRI and CT imaging combined with VI-RADS and artificial intelligence in diagnosis and efficacy evaluation of bladder cancer - Multicenter study of MRI and CT combined with VI-RADS and AI in diagnosis and efficacy evaluation of bladder cancer

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300079011

Enrollment

Unknown

Registered

2023-12-22

Start date

2022-11-09

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

Gold Standard:Postoperative pathology

Index test:Multiparameter magnetic resonance imaging, tumor contact length, Computed tomography urography

Eligibility

Sex/Gender

All

Age

25 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.The patient did not have any serious heart, liver , or kidney diseases, and there were no contraindications to MRI/CTU scanning. 2.The patient underwent radical cystectomy, partial cystectomy, or transurethral resection of the bladder tumor (TURBT) and was pathologically confirmed as a case of bladder cancer. 3.The patient did not undergo cystoscopic biopsy or chemotherapy infusion within 2 weeks prior to MRI/CTU. 4.After MRI/CTU, the patient underwent surgery within 2 weeks.

Exclusion criteria

Exclusion criteria: 1.There were no pathologically confirmed cases, benign cases, and other bladder tumors that were not bladder cancer. 2.Cases with more missing clinical data. 3.Cases with obvious artifact interference and blurred images. 4.The bleeding signal of cystoscopy biopsy before MRI/CTU affects the image analysis. 5.Cases of bladder infusion chemotherapy in a short period before surgery.

Design outcomes

Primary

Measure	Time frame
VI-RADS;MRI and CTU;	—

Secondary

Measure	Time frame
tumor contact length;	—

Countries

China

Contacts

Public ContactJianjun Zhou

Zhongshan Hospital Fudan University

zhoujianjunzs@126.com+86 21 6404 1990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026